enGene
0 followers
ENGN
Performance
About enGene
enGene is a biotechnology company focused on mainstreaming non-viral genetic medicines, developing detalimogene for non-muscle invasive bladder cancer (NMIBC). The company emphasizes delivering non-viral gene therapy directly to mucosal tissues to reduce treatment burden and improve patient outcomes, with clinical development including the LEGEND program and RMAT/Fast Track designations from the FDA. Headquartered in the United States, enGene highlights its DDX platform and a patient-centered approach to advancing genetic medicines for urological cancers and beyond.
Recent News
Recent Deals
No recent deals for this company.